Welcome to our dedicated page for Mind Medicine (MindMed) Common Shares news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine (MindMed) Common Shares stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a biopharmaceutical company based in New York, specializing in the development of psychedelic-inspired medicines and therapies, known as psychoplastogens. The company's core mission is to address major mental health issues like addiction and mental illnesses through innovative treatments.
MindMed is at the forefront of a growing industry, assembling a comprehensive drug development pipeline focused on psychoplastogens. These substances have shown great potential in treating brain health disorders, and MindMed is committed to rigorous scientific research to unlock their therapeutic benefits.
One of the company's most significant recent achievements is the positive data from its Phase 2b clinical trial of MM120 (lysergide d-tartrate) for treating generalized anxiety disorder (GAD). The trial results indicated a substantial improvement in participants, with 48% achieving remission and 65% showing clinically meaningful improvement four weeks after a single dose. This breakthrough has led the U.S. Food and Drug Administration (FDA) to designate MM120 for GAD as a breakthrough therapy, reflecting the significant unmet medical need in this area.
MindMed collaborates extensively with other organizations and clinical research sites, such as Numinus Wellness Inc., to advance its clinical trials. With a research network spanning 20 sites and involving 198 participants, MindMed ensures robust and reliable clinical data.
The company's approach is unique, focusing purely on the effects of its treatments without the interference of other medications or therapies. This has allowed for a clear understanding of the efficacy and potential of their psychedelic-inspired medicines.
Financially, MindMed is well-positioned to continue its pioneering work. The company leverages its partnerships and collaborations to support its research and development efforts, aiming to bring these novel treatments to market.
With a vision to transform mental health care, MindMed is leading the way in integrating psychedelic-assisted therapies into mainstream clinical practice. The company’s ongoing projects and positive clinical outcomes signal a promising future in addressing some of the most prevalent mental health disorders.
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has announced a conference call and webcast scheduled for August 13, 2024, at 8:00 a.m. ET. The event will provide a corporate update and review the company's second quarter 2024 financial results for the period ending June 30, 2024. Interested parties can register for the webcast through a provided link, while analysts wishing to participate in the Q&A session have a separate registration link. A replay of the webcast will be available on MindMed's investor relations website for at least 30 days after the event. Participants are advised to join 15 minutes before the start time.
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on brain health disorders, has appointed Stephanie Fagan as Chief Corporate Affairs Officer. Fagan, with over 20 years of healthcare industry experience, will oversee public affairs and corporate communications. She joins from Agenus and has previously held senior positions at Acadia Pharmaceuticals, bluebird bio, Alexion, and other major healthcare companies.
CEO Rob Barrow emphasized the importance of Fagan's role as MindMed advances MM120 into pivotal trials. As part of her appointment, Fagan received inducement awards including 60,000 time-based restricted stock units (RSUs) and an option to purchase 110,000 common shares. These awards will vest over a four-year period, subject to continuous employment.
MindMed (NASDAQ: MNMD) has been granted a new patent by the USPTO for its MM120 (lysergide) orally disintegrating tablet (ODT) formulation. This patent, extending protection until 2041, covers the pharmaceutical formulation, manufacturing methods, and treatment applications for MM120 ODT. The formulation incorporates Catalent's Zydis® ODT technology, which MindMed believes will offer pharmacological advantages including faster absorption, improved bioavailability, and reduced gastrointestinal side effects.
MM120 is currently in clinical development for generalized anxiety disorder (GAD) and shows potential for treating other brain health disorders. MindMed holds exclusive rights to the Zydis technology for lysergide in several key markets. CEO Rob Barrow emphasized the importance of this patent in extending IP protection and highlighting the unique properties of the MM120 ODT formulation.
Mind Medicine (MindMed) (NASDAQ: MNMD), a clinical stage biopharmaceutical company focused on brain health disorders, announced its inclusion in the Russell 2000® and Russell 3000® Indexes. This inclusion is part of the annual reconstitution of the Russell stock indexes, effective today. CEO Rob Barrow highlighted this milestone as a reflection of MindMed's commitment to treating anxiety and autism spectrum disorders through its product candidates MM120 and MM402. The Russell 3000® Index includes the 3,000 largest U.S.-traded stocks, and membership ensures automatic inclusion in the appropriate large-cap or small-cap indexes. This is significant as $9.1 trillion in assets are benchmarked against these indexes, providing greater visibility for MindMed among investment managers and institutional investors.
MindMed, a clinical-stage biopharmaceutical company, revealed that its management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference. This event takes place on June 27, 2024. The presentation will be accessible via a webcast on MindMed’s Investor Relations website starting at 7:00 AM ET on the same date. The webcast will remain available for replay for up to 90 days post-event.
MindMed has completed its End-of-Phase 2 meeting with the FDA for MM120, intended for treating Generalized Anxiety Disorder (GAD).
The FDA has aligned with MindMed on the requirements for Phase 3 clinical trials, set to begin in the second half of 2024.
The Phase 2b trial of MM120 showed significant results with a 65% clinical response rate and 48% clinical remission rate at Week 12.
MM120 was generally well-tolerated, with adverse events being mild to moderate and transient.
This advancement marks a important milestone for MindMed and the millions affected by GAD globally.
MindMed (NASDAQ: MNMD), a clinical stage biopharmaceutical company focusing on brain health disorders, announced its participation in two significant June conferences. The first is the BIO International Convention 2024 in San Diego, CA, where they will join the panel 'Challenging Biotech’s One-Track Mind When it Comes to Neuropsychiatric Drug Innovation' on June 4, 2024. The second is the Jefferies 2024 Global Healthcare Conference in New York, NY, where they will engage in 1x1 investor meetings on June 5-6, 2024.
MindMed, a clinical stage biopharmaceutical company (NASDAQ: MNMD), will participate in investor conferences in May, including the 2024 RBCCM Global Healthcare Conference and HCW's 2nd Annual BioConnect Investor Conference. Members of the management team will engage in fireside chats and 1x1 investor meetings to discuss novel product candidates for brain health disorders.
MindMed presented new studies at ISPOR 24 revealing the significant impact of Generalized Anxiety Disorder (GAD) in the US. The studies showed that GAD diagnosis increases healthcare costs, decreases work productivity, and diminishes health-related quality of life. Undiagnosed GAD patients incur even higher healthcare costs. MindMed is investigating new treatments for GAD and other brain health disorders.
MindMed reported positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), receiving Breakthrough Therapy Designation from the FDA. Cash and cash equivalents were $252.3 million as of March 31, 2024. The Company is on track to initiate its Phase 3 program for MM120 in GAD in the second half of 2024. MindMed completed a $175.0 million offering, delisted from Cboe Canada, and continues trading on Nasdaq under the symbol 'MNMD'. The Company announced favorable results for MM120 and MM402 programs, with detailed plans and updates on clinical trials and FDA meetings.
FAQ
What is the current stock price of Mind Medicine (MindMed) Common Shares (MNMD)?
What is the market cap of Mind Medicine (MindMed) Common Shares (MNMD)?
What does Mind Medicine (MindMed) Inc. do?
What is MM120?
What were the results of the Phase 2b clinical trial for MM120?
What is the FDA's designation for MM120?
Who are MindMed's partners in clinical research?
What are psychoplastogens?
Where is MindMed based?
What mental health issues does MindMed focus on?
How does MindMed's approach differ in clinical trials?
What is the significance of MindMed's recent achievements?
